Compassionate Use of Sodium Stibogluconate (Pentostam) for Cutaneous and Mucocutaneous New World Leishmaniasis

• Conditions: Leishmaniasis, Cutaneous; Leishmaniasis, Mucocutaneous

• Registration Number: NCT00508963
• Lead Sponsor: University of California, San Francisco

Brief Summary

Patients with biopsy proven new world cutaneous or mucocutaneous leishmaniasis will be treated with sodium stibogluconate (Pentostam).

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2007-07-27
• Study First Submitted QC: 2007-07-27
• Study First Posted: 2007-07-30
• Status Verified: 2023-05
• Last Update Submitted: 2023-12-19
• Last Update Posted: 2023-12-27

Recruitment & Eligibility

• Status: NO_LONGER_AVAILABLE
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

• Biopsy proven new world cutaneous or mucocutaneous leishmania

Exclusion Criteria

• Prolonged QT
• Liver disease
• Pancreatitis

Study & Design

• Study Type: EXPANDED_ACCESS
• Study Design: Not specified

Trial Locations

Locations (1)

University of CA at San Francisco Hospitals and Clinics; 🇺🇸 San Francisco, California, United States